Cancer clinical trials in the region Île-de-France

737 currently recruiting clinical trials
Region Île-de-France
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT02029001 #2012-004510-34
Cohorte Olaparib
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM BRCA 1/2 PALB2 Other mutation
Required number of previous lines of therapy
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Centre Léon Bérard
Phase 2 Liver and bile duct cancer #NCT07219459 #2025-520675-86-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
CatalYm GmbH
Phase 2 Breast cancer Lung cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07492680 #2025-524285-18-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Bristol-Myers Squibb
Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT07475806 #2025-524488-18-00
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Radiotherapy
7 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 2 Breast cancer #NCT07413939 #2025-524498-17-00
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Hoffmann-La Roche
Phase 2 Lung cancer #NCT06855771
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Bristol-Myers Squibb
Phase 2 Colon cancer Rectal cancer #NCT07150403 #2025-522108-26-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded genetic anomalies
MSI/dMMR
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
Fédération Francophone de Cancérologie Digestive
Phase 2 Stomach and esophageal cancer #NCT06846346 #2025-520694-39-00
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2 HER2
Required number of previous lines of therapy for current stage of disease
1
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
MSI/dMMR
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
UNICANCER
Phase 2 Stomach and esophageal cancer #NCT06846346 #2025-520694-39-00
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
Claudin 18.2 HER2 MSI/dMMR
8 recruiting sites
UNICANCER
Phase 2 Head and neck cancer #NCT06640725 #2023-510559-41-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
7 recruiting sites
Groupe Oncologie Radiothérapie Tête et Cou (GORTEC)